155 related articles for article (PubMed ID: 12539478)
1. [A study on tongue cancer cell labeling using bromodeoxyuridine (BrdU) incorporation in vitro].
Li X; Zhao Q; He R; Zhou X; Chen W
Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Oct; 19(5):278-80. PubMed ID: 12539478
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma.
Ghazvini S; Kroll S; Char DH; Frigillana H
Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2762-7. PubMed ID: 7499099
[TBL] [Abstract][Full Text] [Related]
3. [Cell kinetic analysis of human brain tumors by bivariate flow cytometric measurement of cellular DNA content and amount of incorporated bromodeoxyuridine].
Okuda Y; Taomoto K; Saya H; Ijichi A; Kudo H; Kokunai T; Tamaki N; Matsumoto S
No To Shinkei; 1989 Apr; 41(4):383-90. PubMed ID: 2765301
[TBL] [Abstract][Full Text] [Related]
4. Low doses of bromo- and iododeoxyuridine produce near-saturation labeling of adult proliferative populations in the dentate gyrus.
Burns KA; Kuan CY
Eur J Neurosci; 2005 Feb; 21(3):803-7. PubMed ID: 15733099
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of proliferative cells.
Mokrý J; Nĕmecek S
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626
[TBL] [Abstract][Full Text] [Related]
6. NTP Hepatotoxicity Studies of the Liver Carcinogen Methapyrilene Hydrochloride (CAS No. 135-23-9) Administered in Feed to Male F344/N Rats.
Toxic Rep Ser; 2000 Feb; 46():1-C7. PubMed ID: 11986676
[TBL] [Abstract][Full Text] [Related]
7. Quantification of hepatocytic proliferation in the laboratory mouse. A comparative study using immunohistochemical detection of bromodeoxyuridine (BrdU) incorporation and proliferating cell nuclear antigen (PCNA) expression.
Lardelli P; Perentes E; Meier G; Navarro N; Ettlin RA
Exp Toxicol Pathol; 1994 Jul; 46(2):95-100. PubMed ID: 7987078
[TBL] [Abstract][Full Text] [Related]
8. [Postnatal cell proliferation in the rat cerebrum: immunohistochemical study with bromodeoxyuridine (BrdU)].
Fujita T; Yoshimine T; Hayakawa T; Ushio Y; Takemoto O; Maruno M; Kano M; Mogami H
No To Shinkei; 1988 Jul; 40(7):651-5. PubMed ID: 3066383
[TBL] [Abstract][Full Text] [Related]
9. Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia.
Gore SD; Weng LJ; Burke PJ
Exp Hematol; 1993 Dec; 21(13):1702-8. PubMed ID: 7694870
[TBL] [Abstract][Full Text] [Related]
10. Esophageal and gastric cardia epithelial cell proliferation in northern Chinese subjects living in a high-incidence area.
Wang LD; Zhou Q; Yang CS
J Cell Biochem Suppl; 1997; 28-29():159-65. PubMed ID: 9589362
[TBL] [Abstract][Full Text] [Related]
11. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
[TBL] [Abstract][Full Text] [Related]
12. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.
Lee KS; Yang WI
Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339
[TBL] [Abstract][Full Text] [Related]
13. Mucocutaneous junction as the major source of replacement palpebral conjunctival epithelial cells.
Wirtschafter JD; Ketcham JM; Weinstock RJ; Tabesh T; McLoon LK
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3138-46. PubMed ID: 10586935
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue.
Wijsman JH; Van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ
J Pathol; 1992 Sep; 168(1):75-83. PubMed ID: 1360499
[TBL] [Abstract][Full Text] [Related]
15. The possible use for immunohistochemical detection of cells in S-phase labeled by bromodeoxyuridine.
Mokrý J; Nĕmecek S; Adler J; Pokorná P
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1993; 36(1-2):5-15. PubMed ID: 8165431
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry after bromodeoxyuridine labeling to measure S and G2+M phase durations plus doubling times in vitro and in vivo.
Terry NH; White RA
Nat Protoc; 2006; 1(2):859-69. PubMed ID: 17406318
[TBL] [Abstract][Full Text] [Related]
17. The effect of incubation of rectal biopsies on measures of proliferation using proliferating cell nuclear antigen in comparison with 5-bromo-2-deoxyuridine.
Kilias D; Macrae FA; Sharpe K; Young GP
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):819-24. PubMed ID: 9332765
[TBL] [Abstract][Full Text] [Related]
18. Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention.
Risio M
J Cell Biochem Suppl; 1994; 19():61-7. PubMed ID: 7823607
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma.
Kang SM; Kim WH; Kim CW; Kim YI
J Korean Med Sci; 1994 Feb; 9(1):16-20. PubMed ID: 7915118
[TBL] [Abstract][Full Text] [Related]
20. [Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the analysis of tumor cell kinetics by flow cytometry].
Kanno M; Takeda Y; Nakamura S
Nihon Rinsho; 1992 Oct; 50(10):2333-7. PubMed ID: 1280304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
